First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.

Peter Schmid Nicholas C Turner Carlos Henrique Barrios Steven Jay Isakoff Sung-Bae Kim Marie-Paule Sablin Shigehira Saji Peter Savas Gregory A Vidal Mafalda Oliveira Joyce O'Shaughnessy Antoine Italiano Enrique Espinosa Valentina Boni Shane White Beatriz Rojas Rui Gilberto Ferreira Yee Soo Chae Igor Bondarenko Jieun Lee Cesar Torres Mattos Jorge Luis Martinez Rodriguez Lisa H Lam Surai Jones Sarah-Jayne Reilly Xiayu Huang Kalpit Shah Rebecca A Dent

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

In patients with mTNBC receiving an ipatasertib/atezolizumab/taxane triplet regimen, molecular characteristics may identify those with particularly favorable or unfavorable outcomes, potentially guiding future research efforts.

Keyphrases

energy transfer
metastatic breast cancer
squamous cell carcinoma
small cell lung cancer
current status
quality improvement
type diabetes
metabolic syndrome
quantum dots